Literature DB >> 16345057

Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors.

Byron J Gajewski1, Matthew S Mayo.   

Abstract

A number of researchers have discussed phase II clinical trials from a Bayesian perspective. A recent article by Mayo and Gajewski focuses on sample size calculations, which they determine by specifying an informative prior distribution and then calculating a posterior probability that the true response will exceed a prespecified target. In this article, we extend these sample size calculations to include a mixture of informative prior distributions. The mixture comes from several sources of information. For example consider information from two (or more) clinicians. The first clinician is pessimistic about the drug and the second clinician is optimistic. We tabulate the results for sample size design using the fact that the simple mixture of Betas is a conjugate family for the Beta- Binomial model. We discuss the theoretical framework for these types of Bayesian designs and show that the Bayesian designs in this paper approximate this theoretical framework. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16345057     DOI: 10.1002/sim.2450

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  A predictive probability design for phase II cancer clinical trials.

Authors:  J Jack Lee; Diane D Liu
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

2.  Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.

Authors:  Wei Jiang; Jo A Wick; Jianghua He; Jonathan D Mahnken; Matthew S Mayo
Journal:  J Biopharm Stat       Date:  2017-11-27       Impact factor: 1.051

3.  Bayesian approach for sample size determination, illustrated with Soil Health Card data of Andhra Pradesh (India).

Authors:  D J Brus; B Kempen; D Rossiter; A J McDonald
Journal:  Geoderma       Date:  2022-01-01       Impact factor: 6.114

4.  Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.

Authors:  Yu Wang; James Travis; Byron Gajewski
Journal:  BMC Med Res Methodol       Date:  2022-04-21       Impact factor: 4.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.